Pfizer and BioNTech Have Enrolled 83% of Their Up-Sized Coronavirus Vaccine Trial
The partners may not complete enrollment before Moderna, but they do have a lead in one critical enrollment measurement.
Full Article
Pfizer and BioNTech Have Enrolled 83% of Their Up-Sized Coronavirus Vaccine Trial
Motley Fool
0 shares
1 views
You might like
Related news coverage
Why Pfizer Stock Dropped Today
Motley Fool
Investors are still waiting on data from Pfizer's ongoing clinical trial for its coronavirus vaccine candidate.
-
Pfizer's CEO repeatedly talked up getting coronavirus vaccine data in October. Now, he's asking for patience.
Business Insider
-
Pfizer's late-stage coronavirus vaccine trial is near complete enrollment with 42,000 volunteers
Upworthy
-
Inside The U.S.' First COVID-19 Vaccine Clinical Trial For Kids
Newsy
-
Coronavirus updates: Chicago curfew begins Friday night; Pfizer adds teens to vaccine trial; NBA Draft to go virtual; 223K US deaths
USATODAY.com
Advertisement
More coverage
Moderna Eyes December For U.S. Permission For Vaccine Use
Newsy
Watch VideoThe CEO of Moderna says its COVID-19 vaccine could get the thumbs up for emergency use by the end of the..
-
Pfizer hopes to produce 100mln COVID-19 vaccine doses before 2021
Proactive Investors
-
US stocks close sharply lower as coronavirus deal deadline looms
Proactive Investors
-
Markets give back early gains as coronavirus deal deadline looms
Proactive Investors
-
US stocks end mixed as DJIA notches first daily gain in four sessions on strong US consumer data
Proactive Investors